Literature DB >> 7695280

In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir.

S K Spangler1, M R Jacobs, P C Appelbaum.   

Abstract

In vitro susceptibility of 185 penicillin-susceptible and -resistant pneumococci to WY-49605, a new oral penem, was compared with susceptibility to penicillin G, amoxicillin with and without clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir. WY-49605 yielded MICs for 50 and 90% of the strains tested (MIC50 and MIC90, respectively) of 0.03 and 0.06, 0.125 and 0.5, and 0.5 and 1.0 micrograms/ml, respectively, against penicillin-susceptible, intermediately resistant, and fully resistant strains, respectively. The MIC50 and MIC90 for both amoxicillin and amoxicillin-clavulanate were identical and approximately 1 doubling dilution higher than those for WY-49605 and were < or = 0.06 and 0.125, 0.25 and 1.0, and 1.0 and 1.0 micrograms/ml, respectively. Cephalosporin MIC90s were all significantly higher than those of the latter three compounds for intermediately resistant and fully resistant strains.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7695280      PMCID: PMC188304          DOI: 10.1128/AAC.38.12.2902

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

1.  Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics.

Authors:  J Liñares; T Alonso; J L Pérez; J Ayats; M A Domínguez; R Pallarés; R Martín
Journal:  J Antimicrob Chemother       Date:  1992-09       Impact factor: 5.790

2.  Studies on penem antibiotics. II. In vitro activity of SUN5555, a new oral penem.

Authors:  T Nishino; Y Maeda; E Ohtsu; S Koizuka; T Nishihara; H Adachi; K Okamoto; M Ishiguro
Journal:  J Antibiot (Tokyo)       Date:  1989-06       Impact factor: 2.649

Review 3.  Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae.

Authors:  M R Jacobs
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

4.  Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990).

Authors:  J Liñares; R Pallares; T Alonso; J L Perez; J Ayats; F Gudiol; P F Viladrich; R Martin
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

5.  Susceptibility of anaerobic bacteria to ALP 201.

Authors:  C E Nord; A Lindmark; I Persson
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

6.  Comparative in vitro activity of the new oral penem ALP-201 against aerobic and anaerobic bacteria.

Authors:  M Rylander; C E Nord; S R Norrby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

Review 7.  Antimicrobial resistance in Streptococcus pneumoniae: an overview.

Authors:  P C Appelbaum
Journal:  Clin Infect Dis       Date:  1992-07       Impact factor: 9.079

8.  Comparative antibacterial activity of the penem ALP 201.

Authors:  T Bergan; J da Fonseca
Journal:  Chemotherapy       Date:  1991       Impact factor: 2.544

  8 in total
  15 in total

1.  Streptococcus pneumoniae: Activity of Newer Agents Against Penicillin-Resistant Strains.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

2.  Susceptibilities of 228 penicillin- and erythromycin-susceptible and -resistant pneumococci to RU 64004, a new ketolide, compared with susceptibilities to 16 other agents.

Authors:  L M Ednie; S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 3.  Emerging resistance to antimicrobial agents in gram-positive bacteria. Pneumococci.

Authors:  P C Appelbaum
Journal:  Drugs       Date:  1996       Impact factor: 9.546

4.  Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study.

Authors:  G V Doern; A Brueggemann; H P Holley; A M Rauch
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

5.  Antimicrobial activity of DU-6681a, a parent compound of novel oral carbapenem DZ-2640.

Authors:  M Tanaka; M Hohmura; T Nishi; K Sato; I Hayakawa
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

6.  Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

Authors:  Ian A Critchley; James A Karlowsky; Deborah C Draghi; Mark E Jones; Clyde Thornsberry; Kate Murfitt; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

7.  Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents.

Authors:  G A Pankuch; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

8.  Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

9.  Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 250 invasive Streptococcus pneumoniae isolates from France.

Authors:  J W Decousser; P Pina; F Picot; P Y Allouch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-08-27       Impact factor: 3.267

10.  In vitro selection of one-step mutants of Streptococcus pneumoniae resistant to different oral beta-lactam antibiotics is associated with alterations of PBP2x.

Authors:  F Sifaoui; M D Kitzis; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.